Novel Biomarkers and Therapeutic Avenues for Precision Oncology and Effective Treatment Strategies

Md Anisul Islam Khan; Nur A Zannat

doi:10.25163/angiotherapy.81110065

Angiogenesis, Inflammation & Therapeutics | Online ISSN 2207-872X

REVIEWS (Open Access)

Previous Next Contents Vol 8 (11)

Novel Biomarkers and Therapeutic Avenues for Precision Oncology and Effective Treatment Strategies

Md Anisul Islam Khan ¹*, Nur A Zannat ²

+ Author Affiliations

Journal of Angiotherapy 8 (11) 1-8 https://doi.org/10.25163/angiotherapy.81110065

Submitted: 02 September 2024 Revised: 15 November 2024 Published: 16 November 2024

Abstract

Cancer remains one of the most significant global health challenges, necessitating continuous innovation in its diagnosis and treatment. This review highlights the paradigm shift in cancer research and therapeutic strategies, focusing on the transformative role of novel biomarkers and precision oncology. Advances in high-throughput omics technologies and an enhanced understanding of molecular processes have led to the discovery of diverse cancer biomarkers. These biomarkers transcend traditional histopathological classifications, incorporating genetic, epigenetic, and proteomic insights to refine our understanding of cancer heterogeneity. By leveraging these tumor-specific signatures, oncologists can implement highly personalized diagnostic and therapeutic approaches, enabling early detection, precise prognostication, and the identification of previously unrecognized therapeutic targets. This review also explores the groundbreaking therapeutic modalities that have emerged alongside these biomarkers. Immunotherapies, including immune checkpoint inhibitors and CAR-T cell therapies, have revolutionized cancer treatment by utilizing the immune system to selectively target malignancies. Similarly, gene-editing technologies such as CRISPR-Cas9 offer unprecedented potential for correcting genetic aberrations that drive cancer progression. These innovative strategies not only improve treatment efficacy but also minimize the adverse effects often associated with conventional chemotherapy and radiation therapy. In conclusion, the integration of novel biomarkers with precision oncology is redefining cancer management. Through personalized diagnostics and cutting-edge therapies, oncologists can deliver tailored treatment plans that enhance patient outcomes and quality of life. This review underscores the transformative potential of these advancements, offering a hopeful outlook toward a future where cancer is effectively controlled and, in some cases, even cured.

Keywords: Precision Oncology, Novel Biomarker,. Cancer Targets, Therapeutic Avenues,. Personalized Treatment

References

A. Drilon, T.W. Laetsch, S. Kummar, et al.Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children N Engl J Med, 378 (2018), pp. 731-739

A.M. Goodman, S. Kato, L. Bazhenova, et al.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers Mol Cancer Ther, 16 (2017), pp. 2598-2608

ACTolog in Patients With Solid Cancers (ACTolog). 2016. (Accessed 6/24/2019

Arnold-Forster, A. (2016). A pathology of progress? Locating the historiography of cancer. Br. J. Hist. Sci. 49, 627–634

B. Weidenbusch, G.H.S. Richter, M.S. Kesper, et al.Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy Oncotarget, 9 (2018), pp. 20747-20760

B.C. Worst, C.M. van Tilburg, G.P. Balasubramanian, et al. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study Eur J Cancer, 65 (2016), pp. 91-101

C.M. Lovly, A.K.S. Salama, R. Salgia Tumor Heterogeneity and Therapeutic Resistance Am Soc Clin Oncol Educ Book (2016), pp. E585-e593

Chabner, B. A., and Roberts, T. G. Jr. (2005). Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65–72

Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793-795.

D.T. Le, J.N. Uram, H. Wang, et al.PD-1 Blockade in Tumors with Mismatch-Repair Deficiency N Engl J Med, 372 (2015), pp. 2509-2520

Dagogo-Jack, A.T. Shaw Tumour heterogeneity and resistance to cancer therapies Nat Rev Clin Oncol, 15 (2018), pp. 81-94

D. Von Hoff, J.J. Stephenson Jr., P. Rosen, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers J Clin Oncol, 28 (2010), pp. 4877-4883

G. Heller, R. McCormack, T. Kheoh, et al.Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials J Clin Oncol: Off J Am Soc Clin Oncol, 36 (2018), pp. 572-580

GBD Mortality and Causes of Death Collaborators (2016). Global, regional, and national life expectancy, all-causemortality,and cause-specific mortality for 249causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1459–1544.

Genomic Profiling Tests Cleared by FDA. 2017. (Accessed 7/12/2019, at https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer).

Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., et al. (2018). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer Groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol

Hu, C. M., Aryal, S., Zhang, L. (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1, 323–334

J. Michuda, C. Igartua, T. Taxter, J.S. Bell, R. Pelossof, K. White Transcriptome-based cancer type prediction for tumors of unknown origin J Clin Oncol, 37 (2019), p. 3081-

J. Rodon, J.C. Soria, R. Berger, et al.Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial Nat Med, 25 (2019), pp. 751-758

J.A. Sparano, R.J. Gray, D.F. Makower, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer N Engl J Med, 379 (2018), pp. 111-121

J.D. Merker, G.R. Oxnard, C. Compton, et al.Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review Arch Pathol Lab Med (2018)

J.J. Chabon, A.D. Simmons, A.F. Lovejoy, et al.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients Nat Commun, 7 (2016), p. 11815

K.L. Jhaveri, X.V. Wang, V. Makker, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q Ann Oncol, 30 (2019), pp. 1821-1830

L.J. Jennings, M.E. Arcila, C. Corless, et al.Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American PathologistsJ Mol Diagn, 19 (2017), pp. 341-365

M. Cristofanilli, G.T. Budd, M.J. Ellis, et al.Circulating tumor cells, disease progression, and survival in metastatic breast cancer

M. Garassino, D. Rodriguez-Abreu, S. Gadgeel, et al.OA04.06 Evaluation of TMB in KEYNOTE- 189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC J Thoracic Oncol, 14 (2019), pp. S216-S217

M. Schwaederle, M. Zhao, J.J. Lee, et al.Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis JAMA Oncol, 2 (2016), pp. 1452-1459

M. Schwaederle, M. Zhao, J.J. Lee, et al. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis JAMA Oncol, 2 (2016), pp. 1452-1459

M.M. Li, M. Datto, E.J. Duncavage, et al.Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American PathologistsJ Mol Diagn, 19 (2017), pp. 4-23

N Engl J Med, 351 (2004), pp. 781-791

P. Comoli, P. Pedrazzoli, R. Maccario, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes J Clin Oncol: Off J Am Soc Clin Oncol, 23 (2005), pp. 8942-8949

S. Cooley, F. He, V. Bachanova, et al First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia Blood Adv, 3 (2019), pp. 1970-1980

S. Pabla, J.M. Conroy, M.K. Nesline, et al.Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients J Immunother Cancer, 7 (2019), p. 27

S.A. Rosenberg, J.C. Yang, R.M. Sherry, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin Cancer Res: Off J Am Assoc Cancer Res, 17 (2011), pp. 4550-4557

Scott, A. M., Allison, J. P., and Wolchok, J. D. (2012). Monoclonal antibodies in cancer therapy. Cancer Immun. 12:14

T.J. Hiltermann, M.M. Pore, A. van den Berg, et al.Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor Ann Oncol, 23 (2012), pp. 2937-2942

T.N.M. Schumacher T-cell-receptor gene therapy Nat Rev Immunol, 2 (2002), pp. 512-519

U. Sahin, E. Derhovanessian, M. Miller, et al Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Nature, 547 (2017), pp. 222-226

Vile, R. G., Russell, S. J., and Lemoine, N. R. (2000). Cancer gene therapy: hard lessons and new courses. Gene Ther. 7, 2–8

PDF
Abstract
Export Citation

View Dimensions

View Plumx

View Altmetric

0
Save

0
Citation

118
View

0
Share